About CryoLife (NYSE:CRY)
CryoLife, Inc. is a medical devices company, which engages in the processing and distribution of implantable human tissues for use in cardiac and vascular surgeries. It operates through the Medical Devices and Preservation Services segments. The Medical Devices segment includes BioGlue; BioFoam; On-X products; CardioGenesis cardiac laser therapy; PerClot; PhotoFix, Hemodialysis Reliable Outflow Graft; and ProCol Vascular Bioprosthesis. The Preservation Services segment offers preservation of cardiac and vascular tissues. The company was founded on January 19, 1984 and is headquartered in Kennesaw, GA.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNYSE:CRY
CUSIP22890310
Phone770-419-3355
Debt
Debt-to-Equity Ratio0.81%
Current Ratio4.18%
Quick Ratio3.09%
Price-To-Earnings
Trailing P/E Ratio59.13
Forward P/E Ratio262.78
P/E GrowthN/A
Sales & Book Value
Annual Sales$189.70 million
Price / Sales4.17
Cash Flow$0.7136 per share
Price / Cash33.14
Book Value$8.28 per share
Price / Book2.86
Profitability
EPS (Most Recent Fiscal Year)$0.40
Net Income$3.70 million
Net Margins1.95%
Return on Equity5.93%
Return on Assets3.55%
Miscellaneous
Employees1,000
Outstanding Shares33,460,000
CryoLife (NYSE:CRY) Frequently Asked Questions
What is CryoLife's stock symbol?
CryoLife trades on the New York Stock Exchange (NYSE) under the ticker symbol "CRY."
How were CryoLife's earnings last quarter?
CryoLife (NYSE:CRY) released its quarterly earnings results on Wednesday, March, 7th. The medical equipment provider reported $0.11 EPS for the quarter, hitting the consensus estimate of $0.11. The medical equipment provider earned $52.80 million during the quarter, compared to analyst estimates of $48.40 million. CryoLife had a return on equity of 5.93% and a net margin of 1.95%. The company's quarterly revenue was up 17.3% on a year-over-year basis. During the same period last year, the business posted $0.09 earnings per share. View CryoLife's Earnings History.
When is CryoLife's next earnings date?
What guidance has CryoLife issued on next quarter's earnings?
CryoLife issued an update on its FY18 earnings guidance on Wednesday, March, 7th. The company provided earnings per share guidance of $0.29-0.32 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.38. The company issued revenue guidance of $250-256 million, compared to the consensus revenue estimate of $254.80 million.
What price target have analysts set for CRY?
3 brokerages have issued 1 year price objectives for CryoLife's shares. Their forecasts range from $23.50 to $28.00. On average, they anticipate CryoLife's share price to reach $25.8333 in the next year. View Analyst Ratings for CryoLife.
What are Wall Street analysts saying about CryoLife stock?
Here are some recent quotes from research analysts about CryoLife stock:
- 1. According to Zacks Investment Research, "CryoLife, Inc. is a leader in medical device manufacturing and distribution and in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries. It operates throughout the U.S. and internationally. CryoLife manufactures and distributes BioGlue Surgical Adhesive, an FDA-approved adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in Europe for use in soft tissue repair and has received additional marketing approvals in several other countries throughout the world. CryoLife's BioFoam Surgical Matrix is CE marked in Europe for use as an adjunct to hemostasis in cardiovascular surgery and on abdominal parenchymal tissues (liver and spleen) when control of bleeding by ligature or conventional methods is ineffective or impractical. CryoLife distributes PerClot, a powdered hemostat, in Europe and other select international countries. " (3/13/2018)
- 2. Northland Securities analysts commented, "SER-109 stumbles do not impact the long game, in our view. To us, the attractiveness of MCRB’s C. difficile infection (CDI) programs is more about establishing proof of concept (POC) that the microbiome can be manipulated for therapeutic purposes than their revenue potential. If the IBD and/or cancer immunotherapy programs are successful, we believe far larger commercial opportunities could emerge." (3/8/2018)
- 3. Canaccord Genuity analysts commented, "We are updating our model and now include 2019 estimates. We reiterate our BUY rating and $25 price target." (1/3/2018)
Who are some of CryoLife's key competitors?
Some companies that are related to CryoLife include Mazor Robotics (MZOR), Irhythm Technologies (IRTC), Intersect ENT (XENT), ATRION (ATRI), Orthofix (OFIX), OraSure Technologies (OSUR), Glaukos (GKOS), Luminex (LMNX), K2M Group (KTWO), MiMedx Group (MDXG), LeMaitre Vascular (LMAT), Cardiovascular Systems (CSII), AngioDynamics (ANGO), AtriCure (ATRC), Cerus (CERS), Anika Therapeutics (ANIK), Tactile Systems Technology (TCMD) and SurModics (SRDX).
Who are CryoLife's key executives?
CryoLife's management team includes the folowing people:
- James Patrick Mackin, Chairman, President & Chief Executive Officer
- David Ashley Lee, Chief Operating & Financial Officer, Executive VP
- Scott B. Capps, Vice President-Clinical Research
- Jean F. Holloway, Secretary, Chief Compliance Officer & Senior VP
- James McDermid, Chief Human Resources Officer & Senior VP
Has CryoLife been receiving favorable news coverage?
News articles about CRY stock have been trending somewhat positive on Thursday, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. CryoLife earned a media sentiment score of 0.17 on Accern's scale. They also assigned news stories about the medical equipment provider an impact score of 46.37 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
How do I buy shares of CryoLife?
Shares of CRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CryoLife's stock price today?
One share of CRY stock can currently be purchased for approximately $23.60.
How big of a company is CryoLife?
CryoLife has a market capitalization of $781.23 million and generates $189.70 million in revenue each year. The medical equipment provider earns $3.70 million in net income (profit) each year or $0.40 on an earnings per share basis. CryoLife employs 1,000 workers across the globe.
How can I contact CryoLife?
CryoLife's mailing address is 1655 Roberts Boulevard N.W, Kennesaw GA, 30144. The medical equipment provider can be reached via phone at 770-419-3355.
MarketBeat Community Rating for CryoLife (CRY)
MarketBeat's community ratings are surveys of what our community members think about CryoLife and other stocks. Vote "Outperform" if you believe CRY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRY will underperform the S&P 500 over the long term. You may vote once every thirty days.
CryoLife (NYSE:CRY) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for CryoLife in the last 12 months. Their average twelve-month price target is $25.8333, suggesting that the stock has a possible upside of 9.23%. The high price target for CRY is $28.00 and the low price target for CRY is $23.50. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $25.8333 | $25.8333 | $23.6250 | $23.6250 |
| Price Target Upside: | 9.23% upside | 16.89% upside | 23.69% upside | 1.39% upside |
CryoLife (NYSE:CRY) Consensus Price Target History
CryoLife (NYSE:CRY) Analyst Ratings History
Show:
(Data available from 4/19/2016 forward)
CryoLife (NYSE:CRY) Dividend Information
CryoLife pays an annual dividend of $0.00 per share, with a dividend yield of 0.00%. CRY's most recent quarterly dividend payment was Friday, December 18. CryoLife pays out 0.00% of its earnings out as a dividend.
| Most Recent Dividend: | 12/18/2015 |
| Dividend Yield: | 0.00% |
| Dividend Growth: | 0.00% (3 Year Average) |
| Payout Ratio: | 0.00% (Trailing 12 Months of Earnings)
0.00% (Based on This Year's Estimates)
0.00% (Based on Next Year's Estimates)
|
CryoLife (NYSE:CRY) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 10/22/2015 | quarterly | $0.03 | 1.22% | 12/9/2015 | 12/11/2015 | 12/18/2015 |
| 7/22/2015 | quarterly | $0.03 | 1.07% | 9/9/2015 | 9/11/2015 | 9/18/2015 |
| 5/21/2015 | quarterly | $0.03 | 1.08% | 6/10/2015 | 6/12/2015 | 6/19/2015 |
| 2/13/2015 | quarterly | $0.03 | 1.12% | 3/11/2015 | 3/13/2015 | 3/20/2015 |
| 10/23/2014 | quarterly | $0.03 | 1.14% | 12/10/2014 | 12/12/2014 | 12/19/2014 |
| 7/30/2014 | quarterly | $0.03 | 1.22% | 9/10/2014 | 9/12/2014 | 9/19/2014 |
| 5/22/2014 | quarterly | $0.03 | 1.38% | 6/11/2014 | 6/13/2014 | 6/20/2014 |
| 2/19/2014 | quarterly | $0.0275 | 1.17% | 3/12/2014 | 3/14/2014 | 3/21/2014 |
| 11/21/2013 | quarterly | $0.0275 | 1.05% | 12/11/2013 | 12/13/2013 | 12/20/2013 |
| 8/21/2013 | quarterly | $0.0275 | 1.72% | 9/11/2013 | 9/13/2013 | 9/20/2013 |
| 5/28/2013 | quarterly | $0.0275 | 1.75% | 6/12/2013 | 6/14/2013 | 6/21/2013 |
| 2/13/2013 | quarterly | $0.0250 | 1.61% | 3/12/2013 | 3/14/2013 | 3/21/2013 |
(Data available from 1/1/2013 forward)
CryoLife (NYSE CRY) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 3.97%
Institutional Ownership Percentage: 74.06%
CryoLife (NYSE CRY) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/17/2018 | John E Davis | VP | Sell | 3,333 | $23.00 | $76,659.00 | 54,771 |  |
| 3/8/2018 | C Elkins Ronald | Director | Sell | 2,000 | $22.00 | $44,000.00 | 97,849 | |
| 12/15/2017 | C Elkins Ronald | Director | Sell | 1,000 | $20.00 | $20,000.00 | 99,849 | |
| 11/16/2017 | David C Gale | VP | Sell | 20,000 | $19.63 | $392,600.00 | | |
| 11/8/2017 | Amy Horton | CAO | Sell | 4,000 | $19.00 | $76,000.00 | 98,705 | |
| 11/8/2017 | David Ashley Lee | CFO | Sell | 33,190 | $19.00 | $630,610.00 | 324,339 | |
| 11/6/2017 | C Elkins Ronald | Director | Sell | 1,000 | $19.03 | $19,030.00 | 100,849 | |
| 10/2/2017 | James Benson | Director | Sell | 2,000 | $22.80 | $45,600.00 | | |
| 9/6/2017 | James P Mackin | CEO | Sell | 125,000 | $22.01 | $2,751,250.00 | 398,399 | |
| 9/5/2017 | C Elkins Ronald | Director | Sell | 1,000 | $22.00 | $22,000.00 | 101,849 | |
| 9/5/2017 | James P Mackin | CEO | Sell | 43,050 | $22.09 | $950,974.50 | 398,399 | |
| 6/27/2017 | Amy Horton | VP | Sell | 9,577 | $20.00 | $191,540.00 | 112,282 | |
| 2/22/2017 | Scott B Capps | VP | Sell | 11,083 | $16.40 | $181,761.20 | 128,477 | |
| 7/26/2016 | C Elkins Ronald | Director | Sell | 2,000 | $14.00 | $28,000.00 | 103,586 | |
| 6/1/2016 | Ronald D Mccall | Director | Sell | 10,000 | $11.56 | $115,600.00 | 156,248 | |
| 5/10/2016 | James Benson | Director | Sell | 5,000 | $12.22 | $61,100.00 | 65,352 | |
| 4/15/2016 | C Elkins Ronald | Director | Sell | 1,000 | $12.00 | $12,000.00 | 96,852 | |
| 3/7/2016 | C Elkins Ronald | Director | Sell | 2,000 | $11.18 | $22,360.00 | 97,852 | |
| 3/4/2016 | James P Mackin | CEO | Buy | 10,000 | $10.91 | $109,100.00 | 363,933 | |
| 2/19/2016 | Scott B Capps | VP | Sell | 15,000 | $10.30 | $154,500.00 | 91,873 | |
| 2/18/2016 | David Ashley Lee | CFO | Sell | 8,000 | $10.13 | $81,040.00 | 243,284 | |
| 12/28/2015 | David Ashley Lee | CFO | Sell | 700 | $11.00 | $7,700.00 | 244,269 | |
| 11/30/2015 | David Ashley Lee | CFO | Sell | 11,800 | $11.03 | $130,154.00 | 243,969 | |
| 9/15/2015 | James Benson | Director | Sell | 5,839 | $9.65 | $56,346.35 | 70,352 | |
| 9/11/2015 | James Benson | Director | Sell | 3,359 | $9.65 | $32,414.35 | 76,993 | |
| 2/19/2015 | Steven G Anderson | Chairman | Sell | 30,000 | $10.93 | $327,900.00 | | |
| 12/9/2014 | Bruce G Anderson | VP | Sell | 3,900 | $10.29 | $40,131.00 | | |
| 11/25/2014 | Bruce G Anderson | VP | Sell | 20,211 | $10.11 | $204,333.21 | | |
| 11/5/2014 | C Elkins Ronald | Director | Sell | 4,000 | $10.08 | $40,320.00 | | |
| 11/3/2014 | James Benson | Director | Sell | 10,000 | $10.22 | $102,200.00 | | |
| 9/8/2014 | Bruce G Anderson | VP | Sell | 10,000 | $10.05 | $100,500.00 | | |
| 9/2/2014 | Steven G Anderson | Chairman | Sell | 20,000 | $10.08 | $201,600.00 | | |
| 8/25/2014 | Bruce G Anderson | VP | Sell | 5,000 | $10.05 | $50,250.00 | | |
| 8/18/2014 | Bruce G Anderson | VP | Sell | 10,000 | $10.52 | $105,200.00 | | |
| 8/14/2014 | David Ashley Lee | CFO | Sell | 10,000 | $10.51 | $105,100.00 | | |
| 8/13/2014 | David Ashley Lee | CFO | Sell | 9,881 | $10.51 | $103,849.31 | | |
| 8/13/2014 | Jeffrey W Burris | VP | Sell | 11,000 | $10.50 | $115,500.00 | | |
| 7/29/2014 | C Elkins Ronald | Director | Sell | 2,500 | $9.67 | $24,175.00 | | |
| 7/28/2014 | Bruce G Anderson | VP | Sell | 5,000 | $9.48 | $47,400.00 | | |
| 7/28/2014 | Steven G Anderson | CEO | Sell | 19,477 | $9.52 | $185,421.04 | | |
| 6/9/2014 | Amy Horton | CAO | Sell | 2,500 | $9.26 | $23,150.00 | | |
| 5/16/2014 | David Fronk | VP | Sell | 8,952 | $8.61 | $77,076.72 | 101,528 | |
| 5/13/2014 | Steven Anderson | CEO | Sell | 30,523 | $9.00 | $274,707.00 | 1,385,810 | |
| 5/6/2014 | Bruce Anderson | VP | Sell | 16,870 | $8.83 | $148,962.10 | 34,564 | |
| 11/26/2013 | Jeffrey Burris | VP | Sell | 5,000 | $10.50 | $52,500.00 | 79,099 | |
| 11/11/2013 | Jeffrey Burris | VP | Sell | 5,000 | $10.00 | $50,000.00 | 79,099 | |
| 11/7/2013 | Steven Anderson | CEO | Sell | 100,000 | $9.38 | $938,000.00 | 1,358,120 | |
| 10/29/2013 | C Elkins Ronald | Director | Sell | 2,000 | $9.00 | $18,000.00 | | |
| 10/29/2013 | Jeffrey W Burris | VP | Sell | 5,000 | $9.00 | $45,000.00 | | |
| 8/27/2013 | Bruce Anderson | VP | Sell | 4,500 | $6.33 | $28,485.00 | 36,608 | |
| 8/8/2013 | Amy Horton | CAO | Sell | 2,500 | $7.07 | $17,675.00 | 57,574 | |
| 8/1/2013 | Ronald D Mccall | Director | Sell | 6,000 | $7.10 | $42,600.00 | | |
| 6/6/2013 | Ronald D Mccall | Director | Sell | 4,000 | $6.15 | $24,600.00 | | |
| 5/31/2013 | C Elkins Ronald | Director | Sell | 2,250 | $6.15 | $13,837.50 | | |
(Data available from 1/1/2013 forward)
CryoLife (NYSE CRY) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | CryoLife (CRY) VP John E. Davis Sells 3,333 Shares
www.americanbankingnews.com - April 18 at 7:49 PM |
 | CryoLife Announces Release Date and Teleconference Call Details for 2018 First Quarter Financial Results
finance.yahoo.com - April 17 at 5:20 PM |
| CryoLife (CRY) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - April 17 at 4:11 AM |
| CryoLife (CRY) Rating Lowered to Hold at BidaskClub
www.americanbankingnews.com - April 16 at 8:40 PM |
| Head to Head Analysis: CryoLife (CRY) and Orthofix International (OFIX)
www.americanbankingnews.com - April 15 at 11:15 AM |
| CryoLife (CRY) Downgraded to "Sell" at BidaskClub
www.americanbankingnews.com - April 14 at 6:22 PM |
| Cryolife Inc (CRY) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - April 4 at 9:58 AM |
| Cryolife (CRY) Cut to C+ at TheStreet
www.americanbankingnews.com - April 2 at 3:15 PM |
| Cryolife (CRY) Receives "Buy" Rating from Canaccord Genuity
www.americanbankingnews.com - March 31 at 6:52 AM |
| CryoLife to Present at 17th Annual Needham Healthcare Conference
finance.yahoo.com - March 20 at 9:08 AM |
| Cryolife (CRY) Cut to Sell at ValuEngine
www.americanbankingnews.com - March 19 at 10:40 PM |
| Edited Transcript of CRY earnings conference call or presentation 8-Mar-18 1:00pm GMT
finance.yahoo.com - March 18 at 8:53 AM |
 | Form 4 CRYOLIFE INC For: Mar 12 Filed by: Holloway Jean F
www.streetinsider.com - March 16 at 9:06 AM |
 | Global Wound Closure Market Opportunities 2018: Smith and Nephew plc, Derma Sciences , CryoLife , Medtronic plc
www.marketwatch.com - March 16 at 9:06 AM |
| Cryolife (CRY) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - March 13 at 8:00 PM |
| Cryolife Inc (CRY) to Post Q2 2018 Earnings of $0.01 Per Share, First Analysis Forecasts
www.americanbankingnews.com - March 12 at 3:24 AM |
| Cryolife Inc (CRY) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - March 10 at 7:36 AM |
| Insider Selling: Cryolife Inc (CRY) Director Sells 2,000 Shares of Stock
www.americanbankingnews.com - March 9 at 7:16 PM |
| Cryolife (CRY) Stock Rating Reaffirmed by Canaccord Genuity
www.americanbankingnews.com - March 9 at 8:11 AM |
| Cryolife (CRY) Rating Reiterated by Northland Securities
www.americanbankingnews.com - March 8 at 8:08 PM |
| CryoLife (CRY) Beats Earnings and Revenue Estimates in Q4
finance.yahoo.com - March 8 at 5:56 PM |
| CryoLife Reports Fourth Quarter and Full Year 2017 Results
finance.yahoo.com - March 8 at 9:07 AM |
| CryoLife reports 4Q loss
finance.yahoo.com - March 8 at 9:07 AM |
 | CryoLife EPS in-line, beats on revenue
seekingalpha.com - March 7 at 11:10 PM |
| Cryolife (CRY) Issues FY18 Earnings Guidance
www.americanbankingnews.com - March 7 at 9:14 PM |
| Cryolife (CRY) Posts Quarterly Earnings Results, Hits Expectations
www.americanbankingnews.com - March 7 at 9:14 PM |
| Royce & Associates LP Has $7.43 Million Stake in Cryolife Inc (CRY)
www.americanbankingnews.com - February 28 at 9:42 AM |
| Cryolife (CRY) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - February 28 at 2:52 AM |
| Cryolife Inc (CRY) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - February 13 at 11:04 AM |
 | CryoLife Announces Release Date and Teleconference Call Details for 2017 Fourth Quarter and Year-End Financial Results
www.prnewswire.com - February 12 at 5:40 PM |
| Cryolife (CRY) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - February 6 at 3:12 AM |
| Ocular Therapeutix (OCUL) & Cryolife (CRY) Financial Analysis
www.americanbankingnews.com - February 4 at 1:08 AM |
| Cryolife Inc (CRY) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - January 19 at 8:02 AM |
| Zacks Investment Research Upgrades Cryolife (CRY) to Hold
www.americanbankingnews.com - January 16 at 11:46 PM |
| Insider Selling: Cryolife Inc (CRY) Director Sells 1,000 Shares of Stock
www.americanbankingnews.com - December 19 at 9:48 PM |
| CryoLife, Inc. – Value Analysis (NYSE:CRY) : December 19, 2017
finance.yahoo.com - December 19 at 4:56 PM |
| ETFs with exposure to CryoLife, Inc. : December 18, 2017
finance.yahoo.com - December 18 at 4:55 PM |
| CryoLife, Inc. breached its 50 day moving average in a Bullish Manner : CRY-US : December 18, 2017
finance.yahoo.com - December 18 at 10:15 AM |
| ETFs with exposure to CryoLife, Inc. : December 7, 2017
finance.yahoo.com - December 7 at 5:18 PM |
| CryoLife (CRY) vs. K2M Group (KTWO) Head-To-Head Contrast
www.americanbankingnews.com - December 5 at 5:48 PM |
 | BRIEF-Cryolife Says On Dec 1 Co Entered Into A Credit And Guaranty Agreement
www.reuters.com - December 2 at 4:49 PM |
| CryoLife Completes Acquisition of JOTEC
finance.yahoo.com - December 1 at 5:14 PM |
| CryoLife, Inc. (CRY) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - November 30 at 7:50 AM |
| The Asia-Pacific surgical and medical device market is expected to register a CAGR growth of 6.50% over the forecast period of 2017-2026
finance.yahoo.com - November 29 at 5:17 PM |
| ETFs with exposure to CryoLife, Inc. : November 27, 2017
finance.yahoo.com - November 27 at 6:10 PM |
| Reviewing West Pharmaceutical Services (WST) & CryoLife (CRY)
www.americanbankingnews.com - November 19 at 11:46 PM |
| CryoLife: Good Opportunity To Buy One Of The Better Small-Cap Stocks In The Med Tech Space
seekingalpha.com - November 18 at 5:12 PM |
| CryoLife, Inc. (CRY) to Post Q3 2018 Earnings of $0.02 Per Share, First Analysis Forecasts
www.americanbankingnews.com - November 18 at 12:44 AM |
| David C. Gale Sells 20,000 Shares of CryoLife, Inc. (CRY) Stock
www.americanbankingnews.com - November 17 at 10:26 PM |
| FY2017 EPS Estimates for CryoLife, Inc. (CRY) Lowered by First Analysis
www.americanbankingnews.com - November 15 at 6:58 AM |
CryoLife (NYSE:CRY) SEC Filings
This page is loading this company's SEC Filings. Please wait...
CryoLife (NYSE:CRY) Income Statement, Balance Sheet and Cash Flow Statement
CryoLife (NYSE CRY) Stock Chart for Thursday, April, 19, 2018
Loading chart…
